2024年4月15日 · Here we report that nerve growth factor receptor (NGFR) is upregulated in skeletal cells during OA and plays an essential role in the remodeling and repair of...

2021年7月26日 · Associations between anti-NGF antibody therapy and rapidly progressive OA have prompted research into alternative approaches to target NGF that have improved safety profiles. A new study...

2020年11月20日 · Chronic pain from osteoarthritis (OA) is highly prevalent, and effective non-opioid medications are few. Nerve growth factor (NGF) is an important neurotrophin that activates nociceptive...

In this review, we aimed to give an update on the current clinical and preclinical studies targeting two pathways that are being investigated for treating OA pain: the nerve growth factor (NGF) pathway and the transient receptor potential vanilloid-1 (TRPV1) pathway.

In this review, we present the role of nerve growth factor (NGF) in pain generation, relationship between NGF and OA pain, and pathogenic factors (interleukin-1β, transforming growth factor-β1, mechanical loading, and adipokines) involved in OA development.

2015年1月1日 · To evaluate the efficacy and safety of anti-NGF antibody treatment in hip and knee osteoarthritis (OA), a systematic review and meta-analysis was undertaken utilizing the criteria described by the Cochrane collaboration.

Going for gold to improve anti-NGF therapy in OA Nat Rev Rheumatol. 2021 Sep;17(9):508. doi: 10.1038/s41584-021-00670-7.

NGF, by interacting with tropomyosin receptor kinase A receptor (TrkA), modulates the pain pathway through the enhancement of the neurotrophic and nociceptor functions. Moreover, it has been demonstrated that NGF is upregulated in patients …

For nearly 20 years, monoclonal antibodies against nerve growth factor (NGF-Abs) have been investigated for the treatment of chronic pain, and 3 NGF-Abs (fasinumab, fulranumab, and tanezumab) have advanced into phase 2 clinical testing (note Johnson and Johnson discontinued the fulranumab development program in 2016 as part of a reprioritization...

2019年7月4日 · The anti-nerve growth factor (NGF) antibody fasinumab improved pain and function in patients with osteoarthritis (OA) in a phase III study in the USA. 342 patients with knee or hip OA were...